MZE782 An oral SLC6A19 inhibitor in Phase 2 development for phenylketonuria and chronic kidney disease by reducing neutral amino-acid transport.
Visit productCosigns Received
Be the first Cosign
Put your name behind MZE782.
Add it to your Products I use list and share why you use it.